Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy

Sushma Reddy, Alan Fung, Cedric Manlhiot, Elif Seda Selamet Tierney, Wendy K. Chung, Elizabeth Blume, Beth D. Kaufman, Elizabeth Goldmuntz, Steven Colan, Seema Mital

Research output: Contribution to journalArticle

Abstract

Background:Adrenergic receptor (ADR) genotypes are associated with heart failure (HF) and β-blocker response in adults. We assessed the influence of ADR genotypes in children with dilated cardiomyopathy (DCM).Methods:Ninety-one children with advanced DCM and 44 with stable DCM were genotyped for three ADR genotypes associated with HF risk in adults: α2cdel322-325, β1Arg389, and β2Arg16. Data were analyzed by genotype and β-blocker use. Mean age at enrollment was 8.5 y.Results:One-year event-free survival was 51% in advanced and 80% in stable DCM. High-risk genotypes were associated with higher left ventricular (LV) filling pressures, higher systemic and pulmonary vascular resistance, greater decline in LV ejection fraction (P < 0.05), and a higher frequency of mechanical circulatory support while awaiting transplant (P = 0.05). While β-blockers did not reduce HF severity in the overall cohort, in the subset with multiple high-risk genotypes, those receiving β-blockers showed better preservation of cardiac function and hemodynamics compared with those not receiving β-blockers (interaction P < 0.05).Conclusion:Our study identifies genetic risk markers that may help in the identification of patients at risk for developing decompensated HF and who may benefit from early institution of β-blocker therapy before progression to decompensated HF.

Original languageEnglish (US)
Pages (from-to)363-369
Number of pages7
JournalPediatric research
Volume77
Issue number2
DOIs
StatePublished - Feb 11 2015
Externally publishedYes

Fingerprint

Dilated Cardiomyopathy
Adrenergic Receptors
Heart Failure
Genotype
Vascular Resistance
Ventricular Pressure
Genetic Markers
Stroke Volume
Disease-Free Survival
Hemodynamics
Transplants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy. / Reddy, Sushma; Fung, Alan; Manlhiot, Cedric; Selamet Tierney, Elif Seda; Chung, Wendy K.; Blume, Elizabeth; Kaufman, Beth D.; Goldmuntz, Elizabeth; Colan, Steven; Mital, Seema.

In: Pediatric research, Vol. 77, No. 2, 11.02.2015, p. 363-369.

Research output: Contribution to journalArticle

Reddy, S, Fung, A, Manlhiot, C, Selamet Tierney, ES, Chung, WK, Blume, E, Kaufman, BD, Goldmuntz, E, Colan, S & Mital, S 2015, 'Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy', Pediatric research, vol. 77, no. 2, pp. 363-369. https://doi.org/10.1038/pr.2014.183
Reddy, Sushma ; Fung, Alan ; Manlhiot, Cedric ; Selamet Tierney, Elif Seda ; Chung, Wendy K. ; Blume, Elizabeth ; Kaufman, Beth D. ; Goldmuntz, Elizabeth ; Colan, Steven ; Mital, Seema. / Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy. In: Pediatric research. 2015 ; Vol. 77, No. 2. pp. 363-369.
@article{d31ded94a8af438ca33071ed1fd5a9e8,
title = "Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy",
abstract = "Background:Adrenergic receptor (ADR) genotypes are associated with heart failure (HF) and β-blocker response in adults. We assessed the influence of ADR genotypes in children with dilated cardiomyopathy (DCM).Methods:Ninety-one children with advanced DCM and 44 with stable DCM were genotyped for three ADR genotypes associated with HF risk in adults: α2cdel322-325, β1Arg389, and β2Arg16. Data were analyzed by genotype and β-blocker use. Mean age at enrollment was 8.5 y.Results:One-year event-free survival was 51{\%} in advanced and 80{\%} in stable DCM. High-risk genotypes were associated with higher left ventricular (LV) filling pressures, higher systemic and pulmonary vascular resistance, greater decline in LV ejection fraction (P < 0.05), and a higher frequency of mechanical circulatory support while awaiting transplant (P = 0.05). While β-blockers did not reduce HF severity in the overall cohort, in the subset with multiple high-risk genotypes, those receiving β-blockers showed better preservation of cardiac function and hemodynamics compared with those not receiving β-blockers (interaction P < 0.05).Conclusion:Our study identifies genetic risk markers that may help in the identification of patients at risk for developing decompensated HF and who may benefit from early institution of β-blocker therapy before progression to decompensated HF.",
author = "Sushma Reddy and Alan Fung and Cedric Manlhiot and {Selamet Tierney}, {Elif Seda} and Chung, {Wendy K.} and Elizabeth Blume and Kaufman, {Beth D.} and Elizabeth Goldmuntz and Steven Colan and Seema Mital",
year = "2015",
month = "2",
day = "11",
doi = "10.1038/pr.2014.183",
language = "English (US)",
volume = "77",
pages = "363--369",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy

AU - Reddy, Sushma

AU - Fung, Alan

AU - Manlhiot, Cedric

AU - Selamet Tierney, Elif Seda

AU - Chung, Wendy K.

AU - Blume, Elizabeth

AU - Kaufman, Beth D.

AU - Goldmuntz, Elizabeth

AU - Colan, Steven

AU - Mital, Seema

PY - 2015/2/11

Y1 - 2015/2/11

N2 - Background:Adrenergic receptor (ADR) genotypes are associated with heart failure (HF) and β-blocker response in adults. We assessed the influence of ADR genotypes in children with dilated cardiomyopathy (DCM).Methods:Ninety-one children with advanced DCM and 44 with stable DCM were genotyped for three ADR genotypes associated with HF risk in adults: α2cdel322-325, β1Arg389, and β2Arg16. Data were analyzed by genotype and β-blocker use. Mean age at enrollment was 8.5 y.Results:One-year event-free survival was 51% in advanced and 80% in stable DCM. High-risk genotypes were associated with higher left ventricular (LV) filling pressures, higher systemic and pulmonary vascular resistance, greater decline in LV ejection fraction (P < 0.05), and a higher frequency of mechanical circulatory support while awaiting transplant (P = 0.05). While β-blockers did not reduce HF severity in the overall cohort, in the subset with multiple high-risk genotypes, those receiving β-blockers showed better preservation of cardiac function and hemodynamics compared with those not receiving β-blockers (interaction P < 0.05).Conclusion:Our study identifies genetic risk markers that may help in the identification of patients at risk for developing decompensated HF and who may benefit from early institution of β-blocker therapy before progression to decompensated HF.

AB - Background:Adrenergic receptor (ADR) genotypes are associated with heart failure (HF) and β-blocker response in adults. We assessed the influence of ADR genotypes in children with dilated cardiomyopathy (DCM).Methods:Ninety-one children with advanced DCM and 44 with stable DCM were genotyped for three ADR genotypes associated with HF risk in adults: α2cdel322-325, β1Arg389, and β2Arg16. Data were analyzed by genotype and β-blocker use. Mean age at enrollment was 8.5 y.Results:One-year event-free survival was 51% in advanced and 80% in stable DCM. High-risk genotypes were associated with higher left ventricular (LV) filling pressures, higher systemic and pulmonary vascular resistance, greater decline in LV ejection fraction (P < 0.05), and a higher frequency of mechanical circulatory support while awaiting transplant (P = 0.05). While β-blockers did not reduce HF severity in the overall cohort, in the subset with multiple high-risk genotypes, those receiving β-blockers showed better preservation of cardiac function and hemodynamics compared with those not receiving β-blockers (interaction P < 0.05).Conclusion:Our study identifies genetic risk markers that may help in the identification of patients at risk for developing decompensated HF and who may benefit from early institution of β-blocker therapy before progression to decompensated HF.

UR - http://www.scopus.com/inward/record.url?scp=84927125252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927125252&partnerID=8YFLogxK

U2 - 10.1038/pr.2014.183

DO - 10.1038/pr.2014.183

M3 - Article

C2 - 25406899

AN - SCOPUS:84927125252

VL - 77

SP - 363

EP - 369

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 2

ER -